Literature DB >> 19475547

Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain.

Boxu Yan1, Sean Steen, David Hambly, John Valliere-Douglass, Tim Vanden Bos, Scott Smallwood, Zac Yates, Thomas Arroll, Yihong Han, Himanshu Gadgil, Ramil F Latypov, Alison Wallace, Aiching Lim, Gerd R Kleemann, Weichun Wang, Alain Balland.   

Abstract

We investigated the formation and stability of succinimide, an intermediate of deamidation events, in recombinant monoclonal antibodies (mAbs). During the course of an analytical development study of an IgG1 mAbs, we observed that a specific antibody population could be separated from the main product by cation-exchange (CEX) chromatography. The cell-based bioassay measured a approximately 70% drop in potency for this fraction. Liquid chromatography time-of-flight mass spectrometry (LC-TOF/MS) and tandem mass spectrometry (LC-MS/MS) analyses showed that the modified CEX fraction resulted from the formation of a succinimide intermediate at Asn 55 in the complementarity determining region (CDR) of the heavy chain. Biacore assay revealed a approximately 50% decrease in ligand binding activity for the succinimide-containing Fab with respect to the native Fab. It was found that the succinimide form existed as a stable intermediate with a half-life of approximately 3 h at 37 degrees C and pH 7.6. Stress studies indicated that mildly acidic pH conditions (pH 5) favored succinimide accumulation, causing a gradual loss in potency. Hydrolysis of the succinimide resulted in a further drop in potency. The implications of the succinimide formation at Asn 55, a highly conserved residue among IgG1 (mAbs), are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475547     DOI: 10.1002/jps.21655

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

1.  Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media.

Authors:  Timothy Kaschak; Daniel Boyd; Franklin Lu; Gayle Derfus; Brian Kluck; Bartek Nogal; Craig Emery; Christie Summers; Kai Zheng; Robert Bayer; Ashraf Amanullah; Boxu Yan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 3.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

4.  Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.

Authors:  Sejal Gandhi; Da Ren; Gang Xiao; Pavel Bondarenko; Christopher Sloey; Margaret Speed Ricci; Sampathkumar Krishnan
Journal:  Pharm Res       Date:  2011-08-16       Impact factor: 4.200

Review 5.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

6.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

7.  Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.

Authors:  Mukesh Kumar; Amarnath Chatterjee; Anand P Khedkar; Mutyalasetty Kusumanchi; Laxmi Adhikary
Journal:  J Am Soc Mass Spectrom       Date:  2013-01-03       Impact factor: 3.109

Review 8.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.

Authors:  Yi Du; Alison Walsh; Robin Ehrick; Wei Xu; Kimberly May; Hongcheng Liu
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

9.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

10.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.

Authors:  Yi Wang; Xiaojuan Li; Yan-Hui Liu; Daisy Richardson; Huijuan Li; Mohammed Shameem; Xiaoyu Yang
Journal:  MAbs       Date:  2016-09-06       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.